The effect of resveratrol supplementation on some of cardiovascular risk factors and serum adiponectin in patients with nonalcoholic fatty liver disease

Abstract

Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease which involves a range of liver damages from simple steatosis to non-alcoholic liver steatosis. Steatosis or fatty liver is known as excessive accumulation of triglycerides in the liver without excessive alcohol consumption. Resveratrol is a natural non-flavonoids polyphenol combinated with many beneficial biological effects, such as anti-lipid, anti-glycemic, antithrombotic and anti-atherogenic effects. The aim of this study was to evaluate the effect of resveratrol supplementation on some cardiovascular risk factors and serum adiponectin levels in patients with NAFLD. Methods: This randomized double-blind clinical trial was performed on 50 patients with NAFLD (males & females) aged 20-60 years. Patients were randomly assigned to intervention or placebo groups (25 in each group). The intervention group received two capsuls contained 300 mg trans-resveratrol daily and the placebo group received two placebo capsules containing 300 mg starch daily for 12 weeks. Anthropometric measurements (height, weight and body mass index (BMI)) and serum biochemical variables including lipids profile (ApoB, ApoA-1, ox-LDL), liver enzymes (GGT and ALP), plasminogen activator inhibitor-1 (PAI-1) and hsCRP and adiponectin were assessed at the beginning and end of the study. Atherogenic indices including LDL-C/HDL-C, ApoB/ApoA-1, ox-LDL/ApoB, LDL-C/ox.LDL and AIP (Atherogenic index of plasma) ratios were calculated at the beginning and the end of the study. Daily dietary intake and physical activity data were collected for all participants at baseline, sixth week, and end of the study. Statistical analyzes were performed using: Pearson chi-squaredtest, Independent t-test, Paired t-test, Repeated Measures ANOVA and Analysis of covariance (ANCOVA) Results: There were no significant differences in terms of, dietary intakes physical activity, anthropometric measurments, and biochemical variables except serum adiponectin between two groups at the beginning of the study. Resveratrol supplementation reduced body weight (%1/38, P=0.005) and BMI (%1/30, P=0.01) of subjects significantly compared to the placebo group. No significant differences were observed in serum levels of lipid profiles (ApoB, ApoA-1, ox-LDL), Atherogenic indices (LDL-C/HDL-C, ApoB/ApoA-1, ox-LDL/ApoB, LDL-C/ox-LDL and AIP), liver enzymes (GGT and ALP), PAI-1, hs-CRP and adiponectin between two groups at the end of study (P> 0.05). Conclusion: Resveratrol supplementation in dose and duration use in this study had no significant effects on serum liver enzymes, lipid profiles, atherogenic indices, hsCRP, PAI-1, and adiponectin. Resveratrol supplementation reduced weight and BMI of studied subjects. Other studied are warrented to evaluate longterm and dose dependent effects of resveratrol in NAFLD.